At the news
? NEUTRALIMPACT 2/10 144 filed Nov 2, 2026 at 16:39 ET
Beth Hecht, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 75,000 shares of common stock with an estimated aggregate market value of $803,250. The shares were acquired through vesting of restricted stock units in January 2025, and the proposed sale is scheduled for November 2, 2026. The filing indicates a pre-existing 10b5-1 trading plan, with prior sales under the plan in August, September, and October 2026.
- Beth Hecht, an officer, filed Form 144 to sell 75,000 shares of XERS common stock.
- Estimated aggregate market value of the proposed sale is $803,250.
- Shares were acquired via vesting of restricted stock units between January 3, 2025 and January 31, 2025.
- The proposed sale date is November 2, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access